Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like DNA methylation: A key player in gene expression variation and disease manifestation November 27, 2023 Frequency and quantity of alcohol consumption influence cancer risk December 11, 2025 Machine learning can help close pregnancy drug safety gaps May 27, 2026
DNA methylation: A key player in gene expression variation and disease manifestation November 27, 2023